| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027899 |
| Receipt No. | R000031937 |
| Official scientific title of the study | Investigation for safety and efficacy of a new antiseptic Olanexidine Gluconate in children |
| Date of disclosure of the study information | 2017/06/25 |
| Last modified on | 2018/09/18 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Investigation for safety and efficacy of a new antiseptic Olanexidine Gluconate in children | |
| Title of the study (Brief title) | Investigation for safety and efficacy of a new antiseptic Olanexidine Gluconate in children | |
| Region |
|
|
| Condition | |||
| Condition | Patients who undergo surgery of catheter insertion or inguinal hernia | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | This study was designed to measure the safety and the efficacy of a new antiseptic Olanexidine gluconate in children. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Primary outcome was determined to assess the rate of any adverse effect such as labo data, vital sign, subjective and objective symptom, erythema or irritation of the skin. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | An applicator of 1.5% Olamexidine gluconate is used at surgical site.
The skin site exposed to 1.5% Olamexidine gluconate are inspected daily by the bed side nursse or physician to assess any adverse effect such as labo data, vital sign, subjective and objective symptom, erythema or irritation of the skin. Blood concentration of 1.5% Olamexidine gluconate was measured at 0, 2, 24 hours after surgery to draw AUC curve in patients with catheter insertion. |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1)Children who undergo surgery for catheter insertion or inguinal hernia from 1 to 16 years
of age. (2)No abnormal appearance of the skin for surgical incision. (3)Informed concent was obtained from guardians. |
|||
| Key exclusion criteria | (1)History of drug sensitivity.
(2)History of shock or hypersensitivity against Chlorhexidine gluconate. (3)Patients having cutaneous disease (4)Any patients who was judged as inappropriate candidate to enroll this study |
|||
| Target sample size | 55 | |||
| Research contact person | |
| Name of lead principal investigator | Toshihiko Watanabe |
| Organization | National Center for Child Health and Development |
| Division name | Division of Surgery |
| Address | 2-10-1 Okura,Setagaya-ku, Tokyo 157-8535 |
| TEL | 03-3416-0181 |
| watanabe-ts@ncchd.go.jp | |
| Public contact | |
| Name of contact person | Kyoko Hagino |
| Organization | National Center for Child Health and Development |
| Division name | Division of Medical Research |
| Address | 2-10-1 Okura,Setagaya-ku, Tokyo 157-8535 |
| TEL | 03-3416-0181 |
| Homepage URL | |
| hagino-k@ncchd.go.jp | |
| Sponsor | |
| Institute | National Center for Child Health and Development |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Otsuka Pharmaceutical Factory Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031937 |